

Chronogen, Inc.

[View the current Chronogen, Inc. Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/20909-Chronogen%2C+Inc..html)

(<http://www.bioportfolio.com/biocorporate/20909-Chronogen%2C+Inc..html>)

Contact Details:

2901 Rachel E. Suite 22

Montreal

Quebec

H1W 4A4

Canada

Tel: 1 514-521-9595

Fax: 1 514-521-1579

Email: info@chronogen.com

With an aging population, the prevalence of age-related diseases is expected to mount rapidly over the next decade and new drugs are needed. Cardiovascular and metabolic diseases, cancer, neurodegenerative diseases represent huge markets that Biotech and Pharma companies are targeting.

Initially, Chronogen has focused all activities on the identification and the characterization of longevity target genes, cloned by means of long-lived mutants of the nematode *C. elegans*. For those genes that were also found to be expressed in human cells, Chronogen has developed a series of proprietary technologies and screening assays aimed at the identification of small molecule modulators mimicking the genetic effects obtained in *C. elegans* mutants, or equivalent mouse models. Efforts are now focused on the development of drug candidates, selected through unique screening assays, which modulate the production of molecules responsible for cardiovascular, metabolic and central nervous system diseases: Reactive Oxygen Species (ROS) in oxidative stress and Low density Lipoprotein (LDL) in dyslipidemia. Headquartered in Montreal, Canada, Chronogen now employs over 25 scientists.

BioNews Results for Chronogen, Inc.



- [PRIMECAP Management Top Holdings: Amgen Inc., Eli Lilly and Company, Novartis AG, FedEx Corp., Google Inc., Me](#)
Guru Focus: Nov 22 2009 3:56PM Matching: inc
- [Guru Stocks at 52-Week Low: Genzyme Corp, Apollo Group Inc, Cogent Inc, AMERICAN PUBLIC EDUCATION, INC, Whitne](#)
Guru Focus: Nov 22 2009 5:13PM Matching: inc
- [N.J. index reaches a yearly high](#)
Asbury Park Press: Nov 22 2009 12:49PM Matching: inc
- [Analyst Choice Brings New Analysis on Level 3 Communications Inc., Arris Group Inc., Virgin Media Inc., The South Financial Group Inc., Wynn Resorts Limited and AMAG Pharmaceuticals Inc.](#)

- Individual.com: Nov 21 2009 6:41AM Matching: inc*
- [Stocks That Stand Out For Nov. 20th, 2009 Are ARTS, RFMD, CLDS, ACTC](#)
- Pharmacy Choice: Nov 21 2009 1:27PM Matching: inc*
- [Rothman Research Follow-up Study of Charles Schwab Corp., SIRIUS XM Radio Inc., Aastrom Biosciences Inc., Sonic Corp., Zhone Technologies Inc. and United Community Banks Inc.](#)
- Individual.com: Nov 21 2009 10:22AM Matching: inc*
- [Medical News: KineMed Receives An Investigator-Initiated Study Grant To Further Explore Mechanism\(s\) Of Action Associated With Welchol In Type 2 Diabetes Melli](#)
- BioFind: Nov 21 2009 6:38AM Matching: inc*
- [KineMed Receives An Investigator-Initiated Study Grant To Further Explore Mechanism\(s\) Of Action Associated Wi](#)
- Medical News Today: Nov 21 2009 4:01AM Matching: inc*
- [Benefit raises money for child with cancer](#)
- Southwest Florida Herald Tribune: Nov 20 2009 1:22PM Matching: inc*
- [Check Us Out!!! Sign Up Now For Our Free Newsletter!! BRGO, QSAP, XCEL, XMDC, MTVO, GETA](#)
- Pharmacy Choice: Nov 20 2009 10:26PM Matching: inc*
- [Zacks Sell List Highlights: Hughes Communications Inc., Astec Industries, Inc., Abraxis Bioscience, Inc. and R](#)
- Reuters: Nov 20 2009 12:25AM Matching: inc*
- [Stocks on the move: Consol, Dell, Leap, LogMeIn, Merck, Novavax](#)
- Inside Bay Area: Nov 20 2009 6:36PM Matching: inc*
- [ImmunoGen announces second license agreement with Amgen](#)
- TradingMarkets: Nov 20 2009 7:56PM Matching: inc*
- [The Fortune Financial Global Market Perspective Review on Schnitzer Steel Industries Inc., ViroPharma Inc., T.](#)
- TradingMarkets: Nov 20 2009 12:58PM Matching: inc*
- [Global market for anti-depressants on a decline](#)
- News-Medical.Net: Nov 20 2009 11:09AM Matching: inc*

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

